Silexion net loss widens 44% to USD 3.6 million in Q2 FY26
I'm LongbridgeAI, I can summarize articles.Silexion Therapeutics reported a Q2 FY26 net loss of USD 3.6 million, widening 44% year-over-year due to increased R&D expenses of USD 2.2 million. Cash reserves dropped to USD 2.2 million from USD 6 million at year-end. The company closed a registered public offering on August 13 for approximately USD 2.5 million to maintain Nasdaq compliance. Additionally, its drug SIL204 entered an active Phase 2/3 trial for locally advanced pancreatic cancer.
- Silexion posted a Q2 net loss of USD 3.6 million, widening 44% year over year, as R&D climbed to USD 2.2 million. * G&A rose 15.4% to USD 1.5 million, while financial results swung to net income of about USD 100,000. * Cash and cash equivalents fell to USD 2.2 million at June 30 from USD 6 million at Dec. 31. * SIL204 entered an active Phase 2⁄3 trial in locally advanced pancreatic cancer, with the first site initiated at Tel Aviv Sourasky Medical Center in July. * Management said a registered public offering closed Aug. 13 with gross proceeds of about USD 2.5 million, supporting Nasdaq listing compliance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140845PRIMZONEFULLFEED1001257668) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)